Should You Buy MRK Stock At $80?

Merck's stock has declined 22% YTD, underperforming the S&P 500 due to lowered 2025 guidance and concerns about Keytruda and Gardasil's long-term growth, specifically weak Gardasil sales in China and Keytruda's nearing patent expiration in 2028. Despite these concerns, the stock appears undervalued based on price-to-sales, price-to-free cash flow, and price-to-earnings ratios compared to the S&P 500, as well as strong profitability and financial stability; however, potential risks remain, including susceptibility to market downturns and potential declines in Gardasil and Keytruda sales.

Analysis

Merck's (MRK) stock has significantly underperformed the S&P 500 year-to-date, registering a 22% decline compared to the index's 1% dip. This downturn is attributed to lowered 2025 guidance and mounting concerns over the long-term growth prospects of its flagship drugs, Keytruda, which faces patent expiration in 2028, and Gardasil, impacted by weak sales in the critical Chinese market. Despite these challenges, Merck's valuation appears notably low; its price-to-sales ratio is 3.1 versus the S&P 500's 3.0, while its price-to-free cash flow ratio of 9.4 starkly contrasts with the S&P 500's 20.5, and its price-to-earnings ratio stands at 11.3 compared to the benchmark's 26.4, suggesting the stock may be undervalued. Revenue growth has been modest, averaging 5.8% over the last three years and 4.1% in the past twelve months, though quarterly revenues recently shrank by 1.6%. Conversely, Merck exhibits exceptional profitability, with an operating margin of 31.9% and a net income margin of 27.3%, substantially outperforming S&P 500 averages. The company's financial stability is considered neutral, with a moderate debt-to-equity ratio of 17.7%. While Merck demonstrated resilience during the 2020 and 2022 market downturns, outperforming the S&P 500, it experienced a severe 65.5% drop during the 2008 financial crisis. The article suggests that current negative factors may already be incorporated into the stock price, assessing Merck's overall fundamental strength as "Strong," driven by "Very Strong" profitability, despite neutral growth and financial stability.

Key Decisions for Investors

• Investors could consider Merck's current valuation as potentially attractive, given its significantly lower price-to-free cash flow and price-to-earnings ratios compared to the S&P 500, suggesting that recent underperformance and known headwinds may be priced in.
• It is crucial to weigh the appealing valuation and robust profitability against substantial risks, including the Keytruda patent cliff post-2028, ongoing challenges with Gardasil sales in China, and the stock's demonstrated susceptibility to severe market downturns, as seen in 2008.
• Monitor upcoming earnings releases for catalysts such as updates on Gardasil's performance in China, Keytruda's sales momentum, any revisions to the 2025 guidance, and strategic initiatives to address future revenue gaps.